Financial Performance - The total operating revenue for 2024 was RMB 246.99 million, an increase of 20.60% compared to RMB 204.81 million in the previous year[3]. - The net profit attributable to the parent company was a loss of RMB 324.99 million, an increase in loss of RMB 197.05 million year-on-year[5]. - The basic earnings per share were -0.502 yuan, a decline of 152.26% compared to -0.199 yuan in the previous year[8]. - The weighted average return on net assets was -17.15%, a decrease of 11.10 percentage points from -6.05% in the previous year[3]. Assets and Equity - The total assets at the end of the reporting period were RMB 2,284.42 million, a decrease of 12.26% from RMB 2,603.49 million at the beginning of the period[5]. - The equity attributable to the parent company was RMB 1,739.22 million, down 15.50% from RMB 2,058.24 million at the beginning of the period[4]. Operational Challenges - The company faced increased operational costs due to the full production of the Lingang base and the relocation of CDMO business, impacting profitability[6]. - The company executed a strategic relocation of its CDMO business, resulting in asset disposal losses and increased project transfer costs[7]. - The company reported a significant increase in losses due to operational cost increases and impairment losses related to inventory and long-term assets[8]. Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the annual report[9].
和元生物(688238) - 2024 Q4 - 年度业绩